Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests
07 Setembro 2023 - 5:05PM
Business Wire
Veracyte, Inc. (Nasdaq: VCYT) announced that Marie-Claire Taine,
Ph.D., will join Veracyte as general manager of the company’s in
vitro diagnostics (IVD) Business Unit, based in Marseille, France.
She will lead the global expansion of Veracyte’s tests and will
also serve as site lead for the company’s Marseille operations. Dr.
Taine is a highly credentialed commercial operations leader with 30
years of experience in the medical device and pharmaceutical
industries. She will join Veracyte on September 19, reporting to
Marc Stapley, Veracyte’s chief executive officer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230907364591/en/
Veracyte Names Marie-Claire Taine, Ph.D.,
as General Manager of Its IVD Business Unit. (Photo: Business
Wire)
“Dr. Taine’s extensive international management experience and
commercial leadership make her the ideal person to lead the global
expansion of Veracyte’s IVD test menu. She will be key to helping
us achieve our vision of transforming cancer care for patients all
over the world,” said Mr. Stapley.
In the United States, Veracyte offers its market-leading tests
to physicians and their patients through its centralized
laboratories. The company plans to offer select tests as in vitro
diagnostics (IVDs) in Europe and elsewhere so that they may be
performed locally by hospitals and laboratories. Veracyte currently
offers the Prosigna Breast Cancer Assay as an IVD, with additional
tests in development.
Dr. Taine most recently served as vice president, Renal Care,
Europe, and country sponsor, France, for Baxter International Inc.,
after having been president and general manager of the company’s
French entity. At Baxter, she developed and managed implementation
of European business plans, including Europe-wide and country-level
alignment with market access and medical activities, and
collaboration with the company’s European and U.S. operations.
Prior to Baxter, Dr. Taine served as senior vice president of
worldwide commercial operations for medical imaging company
Guerbet, where she also served as president of its medical devices
and French entities. She also previously served as vice president
of Venous Solutions, EMEA, for Covidien, and general manager of
Ultrasound Systems, France & North Africa, for Siemens Medical
Solutions.
Dr. Taine earned her Ph.D. in medical imaging from Paris
XI-Orsay University. She also holds an engineering degree from
Ecole Centrale de Lyon, a diploma from Institut de Formation
Superieure Biomedicale-Villejuif, and an MBA from Institut d’Etudes
Politiques Paris.
“Veracyte has distinguished itself in the U.S., with
market-leading tests that are helping physicians make better
diagnostic and treatment decisions for their patients. I’m thrilled
to join the talented and accomplished team at Veracyte as the
company prepares to expand its impact, benefitting patients
globally,” said Dr. Taine.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose
vision is to transform cancer care for patients all over the world.
We empower clinicians with the high-value insights they need to
guide and assure patients at pivotal moments in the race to
diagnose and treat cancer. Our high-performing tests enable
clinicians to make more confident diagnostic, prognostic, and
treatment decisions for some of the most challenging diseases such
as thyroid, prostate, breast, bladder and lung cancers, as well as
interstitial lung diseases. We help patients avoid unnecessary
procedures and speed time to diagnosis and appropriate treatment.
In addition to making our tests available in the U.S. through our
central laboratories, we also aim to deliver our tests to patients
worldwide through a distributed model to laboratories that can
perform them locally. Veracyte is based in South San Francisco,
California. For more information, please visit www.veracyte.com and
follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to our statements related to our plans,
objectives, expectations (financial and otherwise) or intentions
with respect to our clinical tests in and outside of the United
States. Forward-looking statements can be identified by words such
as: “appears,” "anticipate," "intend," "plan," "expect," "believe,"
"should," "may," "will," “positioned,” “designed” and similar
references to future periods. Examples of forward-looking
statements include, among others, that Dr. Taine will help Veracyte
successfully expand its tests globally and help Veracyte transform
cancer care for patients all over the world. Additional factors
that may impact these forward-looking statements can be found under
the caption “Risk Factors” in our Annual Report on Form 10-K filed
on March 1, 2023, and our Quarterly Report on Form 10-Q filed for
the three months ended June 30, 2023. Copies of these documents,
when available, may be found in the Investors section of our
website at https://investor.veracyte.com. These forward-looking
statements speak only as of the date hereof and, except as required
by law, we specifically disclaim any obligation to update these
forward-looking statements or reasons why actual results might
differ, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230907364591/en/
Investors: investors@veracyte.com 619-393-1545
Media: Tracy Morris VP of Global Corporate Communications
tracy.morris@veracyte.com 650-380-4413
Veracyte (NASDAQ:VCYT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Veracyte (NASDAQ:VCYT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024